vimarsana.com

Latest Breaking News On - Ascentage pharma - Page 1 : vimarsana.com

Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

EHA 2024 | Results from Five Studies of Ascentage Pharma s Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.